Clinical Trial: A First-in-Human Study of HH160 in Patients With Advanced Solid Tumors

U.S., June 4 -- ClinicalTrials.gov registry received information related to the study (NCT07623369) titled 'A First-in-Human Study of HH160 in Patients With Advanced Solid Tumors' on May 29.

Brief Summary: This study is evaluating the safety, side effects, how the body processes HH160, and its early anticancer activity when given alone or with other cancer treatments in participants with advanced solid tumors. The study will also identify the recommended dose for future studies. The trial includes two phases and is expected to last about 4 years, with treatment and follow-up lasting approximately 6-12 months each.

Study Start Date: June, 2026

Study Type: INTERVENTIONAL

Condition: Solid Tumor Non-small Cell Lung Cancer Hepatocellular Ca...